Homepage

After being diagnosed with an aggressive form of leukemia, Ilana Massi defied the odds with the help of her friends and family.

From nurse to patient: facing an aggressive blood cancer

After being diagnosed with an aggressive form of leukemia, Ilana Massi defied the odds with the help ...

Syrian refugees ponder an uncertain future: Zakiya, one of the daughters of Hamid, with her son Waleed, age 10, in their makeshift home.

Stories / Global Impact

Helping Syrian refugees manage chronic diseases

Among the many Syrians uprooted by armed conflict are thousands of people with chronic conditions – ...

Leukemia cells attacked from two angles.

Stories / Discovery

Striving to vanquish leukemia

Combination of two compounds shows promise in the lab

Explore Novartis

Corporate Responsibility

Research & Development

Clinical Pipeline

Recent Updates

Featured / Jun 14

#WeWontRest

As he hands over the Presidency of EFPIA, Novartis CEO Joe Jimenez joins others in pledging the industry’s commitment to improving lives.

Featured News / Jun 22

Asthma and exercise: why patients can and should stay active

More than 300 million people live with asthma globally, and 6 million do not ...

Media Release / May 31

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

Media Release / May 17

Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities

We are pleased to announce the publication of data from our Phase III #AML trial w/ @ALLIANCE_org in @NEJM https://t.co/Zc8xvp7neZ 11 hours 13 min ago

Now presenting at #EHA2017: 96-wk update of ENESTop study in Ph+ #CML-CP patients https://t.co/EeV4uKC2Sv 12 hours 18 min ago

Positive #CHMP opinion for #Novartis advanced breast cancer treatment announced today. Read more: https://t.co/Xxs4X2Uquk 14 hours 33 min ago

Novartis focuses its business on three divisions with innovation power and global scale: innovative medicines, eye care and generics.